Comparing a new long-acting insulin for type 2 diabetes
Treatments studied
Part of Hormones & metabolism clinical trials.
This study tests a new once-daily insulin (GZR4) against an approved insulin (degludec) in people with type 2 diabetes to see how well it controls blood sugar. You may qualify if you are already using a stable dose of background insulin.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have type 2 diabetes and are between 18 and 70 years old.
- You have been using the same basal (long-acting) insulin dose for at least 3 months.
- Your body mass index (BMI) is between 27 and 38.
- Your HbA1c (average blood sugar) is 9.0% or lower.
- You are not pregnant, breastfeeding, or planning to become pregnant.
- You do not have serious health problems like kidney disease, eye disease, or recent severe low blood sugar.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two once-daily insulin injections to see which works better and is safer for people with type 2 diabetes. Both are new types of insulin designed to help control blood sugar with fewer side effects.
This trial tests a new injection (GZR102) compared to two other injections (GZR4 and GZR18) in overweight adults. The goal is to see how well the body processes each drug and their effects. It may help researchers find a better treatment for weight management.
This study tests a new once-daily injection (LC-Z300-01) to see if it can lower blood sugar safely in people with type 2 diabetes. It may be a good option if your current diabetes medications aren't controlling your blood sugar as well as you'd like.
This trial tests different ways to start a new long-acting insulin called icodec for people with type 2 diabetes. It looks at how to give an extra dose on day 4 to help control blood sugar better.
This trial tests if a once-daily injectable combination (iGlarLixi) helps control blood sugar better than usual care for people with type 2 diabetes who are already taking diabetes pills. It aims to find a more effective treatment option.
This study compares a new investigational long-acting insulin (GZR33) to an approved one (insulin degludec) in people with type 1 diabetes. You would receive both insulins during an inpatient 'clamp' procedure to see how well they work, which may help find a more affordable or convenient option for daily blood sugar control.
Hear when a new Type 2 diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.